(Q33391384)

26 July 2017

title

A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer (English)

1 reference

26 July 2017

1 reference

1 reference

Sung Yong Oh

1

1 reference

26 July 2017

Hyuk-Chan Kwon

2

1 reference

26 July 2017

Sang-Ho Jeong

3

1 reference

26 July 2017

Young-Tae Joo

4

1 reference

26 July 2017

Young-Joon Lee

5

1 reference

26 July 2017

Su hee Cho

6

1 reference

26 July 2017

Myoung Hee Kang

7

1 reference

26 July 2017

Se-il Go

8

1 reference

26 July 2017

Gyeong-won Lee

9

1 reference

26 July 2017

Hoon gu Kim

10

1 reference

26 July 2017

Jung Hun Kang

11

1 reference

26 July 2017

publication date

13 August 2010

1 reference

Investigational New Drugs

26 July 2017

published in

1 reference

26 July 2017

volume

30

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

350-356

1 reference

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Initial or delayed chemotherapy with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Phase II study of S-1, a novel oral fluorophyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Cellular and molecular aspects of drugs of the future: oxaliplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

A molecular biological study of anti-tumor mechanisms of an anti-cancer agent Oxaliplatin against established human gastric cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Randomized scheduling feasibility study of S-1 for adjuvant chemotherapy in advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9507-2

Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study).

21 January 2018

1 reference

12 December 2020

Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts

1 reference

12 December 2020

Late phase II study of S-1 in patients with advanced head and neck cancer

1 reference

12 December 2020

Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial

1 reference

12 December 2020

Phase I and pharmacokinetic study of S-1 administered for 14 days in a 21-day cycle in patients with advanced upper gastrointestinal cancer

1 reference

12 December 2020

Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer

1 reference

12 December 2020

Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators

1 reference

12 December 2020

Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group

1 reference

12 December 2020

Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. For the S-1 Cooperative Gastric Cancer Study Group

1 reference

12 December 2020

Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients

1 reference

12 December 2020

Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma

1 reference

12 December 2020

Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo

1 reference

12 December 2020

10.1007/S10637-010-9507-2

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1039747812

0 references

1 reference